Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

These findings are very important for patients with early-stage dMMR tumors because it’s likely they do not need surgery or radiation if they are treated first with immunotherapy for a sufficient ...

MONDAY, June 9, 2025 (HealthDay News) -- For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated with improved survival and ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with standard chemotherapy not only provides a meaningful ...

This evaluation reviews the evidence for dostarlimab with platinum-based chemotherapy for primary advanced or recurrent endometrial cancer when systemic therapy is suitable, which was approved for use ...

Endometrial cancer is the most common gynaecologic cancer in developed countries, 2 with an estimated 1.6 million people living with active disease at any stage and 417,000 new cases reported each ...

The FDA has approved a new drug for some adult patients with endometrial cancer. Jemperli (dostarlimably) — made by U.K. company GSK — is intended for primary advanced or recurrent disease.

The US Food and Drug Administration (FDA) has expanded the approval of dostarlimab-gxly (Jemperli, GSK) in conjunction with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly ...

PHILADELPHIA, August 01, 2024--Expanded approval of Jemperli (dostarlimab-gxly) plus chemo in endometrial cancer as first & only IO-based treatment to show overall survival benefit ...

Background: Dostarlimab (DOST)+carboplatin-paclitaxel (CP) significantly improved PFS and OS vs CP alone in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the phase ...

Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer. News release. GSK.